Leonardo D Borregales1, Dae Y Kim1, Angie L Staller1, Wei Qiao2, Arun Z Thomas1, Mehrad Adibi1, Pheroze Tamboli3, Kanishka Sircar3, Eric Jonasch4, Nizar M Tannir4, Surena F Matin1, Christopher G Wood1, Jose A Karam5. 1. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: JAKaram@mdanderson.org.
Abstract
OBJECTIVE: To study the natural history, prognosticators, and outcomes in patients with renal cell carcinoma (RCC) with extension of tumor beyond Gerota׳s fascia or invading contiguously into the adrenal gland (pT4) or both. PATIENTS AND METHODS: From 1992 to 2012, we identified 61 patients who underwent radical nephrectomy and were found to have pT4 disease. Clinicopathologic variables were queried using univariate analysis to identify relevant prognostic variables. Cox proportional hazards model was used for multivariate analysis of predictors of cancer-specific survival. Survival plots were estimated using Kaplan-Meier method and survival analysis using log-rank test. RESULTS: Median age was 56 years (interquartile range: 49-64) and 49 (81.7%) patients had Eastern Cooperative Oncology Group Performance Status 0 or 1. At diagnosis, 22 (36.1%) patients showed nonmetastatic and 39 (63.9%) patients showed metastatic RCC. Overall, 49 (80.3%) patients had clear cell RCC, 24 (39.3%) patients had sarcomatoid features, and 39 (69.6%) patients had Fuhrman grade 3 to 4. There were 26 (42.6%) patients with pN0, 16 (26.2%) patients with pN1, and 19 (31.1%) patients with pNx. Median cancer-specific survival was 37 months for patients with nonmetastatic and 8 months for patients with metastatic RCC. On multivariate analysis, preoperative lactate dehydrogenase and alkaline phosphatase, M stage, pN stage, and sarcomatoid dedifferentiation were significantly associated with survival. CONCLUSIONS: Survival in patients with pT4 remains poor. The pT4 disease is associated with a locally and regionally invasive biology that requires specific attention and warrants careful study. Understanding the drivers of this unique phenotype would generate therapeutic interventions that can change the behavior of these uniquely aggressive tumors.
OBJECTIVE: To study the natural history, prognosticators, and outcomes in patients with renal cell carcinoma (RCC) with extension of tumor beyond Gerota׳s fascia or invading contiguously into the adrenal gland (pT4) or both. PATIENTS AND METHODS: From 1992 to 2012, we identified 61 patients who underwent radical nephrectomy and were found to have pT4 disease. Clinicopathologic variables were queried using univariate analysis to identify relevant prognostic variables. Cox proportional hazards model was used for multivariate analysis of predictors of cancer-specific survival. Survival plots were estimated using Kaplan-Meier method and survival analysis using log-rank test. RESULTS: Median age was 56 years (interquartile range: 49-64) and 49 (81.7%) patients had Eastern Cooperative Oncology Group Performance Status 0 or 1. At diagnosis, 22 (36.1%) patients showed nonmetastatic and 39 (63.9%) patients showed metastatic RCC. Overall, 49 (80.3%) patients had clear cell RCC, 24 (39.3%) patients had sarcomatoid features, and 39 (69.6%) patients had Fuhrman grade 3 to 4. There were 26 (42.6%) patients with pN0, 16 (26.2%) patients with pN1, and 19 (31.1%) patients with pNx. Median cancer-specific survival was 37 months for patients with nonmetastatic and 8 months for patients with metastatic RCC. On multivariate analysis, preoperative lactate dehydrogenase and alkaline phosphatase, M stage, pN stage, and sarcomatoid dedifferentiation were significantly associated with survival. CONCLUSIONS: Survival in patients with pT4 remains poor. The pT4 disease is associated with a locally and regionally invasive biology that requires specific attention and warrants careful study. Understanding the drivers of this unique phenotype would generate therapeutic interventions that can change the behavior of these uniquely aggressive tumors.
Authors: Grant D Stewart; W Jensen Ang; Alexander Laird; David A Tolley; Antony C P Riddick; S Alan McNeill Journal: BJU Int Date: 2012-01-30 Impact factor: 5.588
Authors: Simon P Kim; Angela L Alt; Christopher J Weight; Brian A Costello; John C Cheville; Christine Lohse; Cristine Allmer; Bradley C Leibovich Journal: J Urol Date: 2011-04-15 Impact factor: 7.450
Authors: Brian Shuch; Jonathan Said; Jeff C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Fairooz F Kabbinaavar; Allan J Pantuck; Arie S Belldegrun Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Brian I Rini; Jorge Garcia; Paul Elson; Laura Wood; Shetal Shah; Andrew Stephenson; Mohammed Salem; Michael Gong; Amr Fergany; John Rabets; Jihad Kaouk; Venkatesh Krishnamurthi; Eric Klein; Robert Dreicer; Steven Campbell Journal: J Urol Date: 2012-03-14 Impact factor: 7.450
Authors: Megan M Merrill; Christopher G Wood; Nizar M Tannir; Rebecca S Slack; Kara N Babaian; Eric Jonasch; Lance C Pagliaro; Zachary Compton; Pheroze Tamboli; Kanishka Sircar; Louis L Pisters; Surena F Matin; Jose A Karam Journal: Urol Oncol Date: 2015-02-17 Impact factor: 3.498
Authors: Maxine Sun; Marco Bianchi; Jens Hansen; Firas Abdollah; Quoc-Dien Trinh; Giovanni Lughezzani; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Int J Urol Date: 2012-10-08 Impact factor: 3.369
Authors: Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau Journal: Can Urol Assoc J Date: 2018-05-31 Impact factor: 1.862
Authors: Justin D Oake; Premal Patel; Luke T Lavallée; Jean-Baptiste Lattouf; Olli Saarela; Laurence Klotz; Ronald B Moore; Anil Kapoor; Antonio Finelli; Ricardo A Rendon; Jun Kawakami; Alan I So; Darrel E Drachenberg Journal: Can Urol Assoc J Date: 2019-07-23 Impact factor: 1.862